Researchers have noted an interesting possible association: as the COVID-19 spread the morbidity and mortality rates appeared to be lower in some developing countries where the BCG vaccine is widely used. Texas A&M investigators are recruiting hundreds of frontline medical workers to participate in a late-stage, Phase 4, clinical trial of a widely used vaccine that could blunt the devastating effects of COVID-19. Chancellor John Sharp offered $2.5 million to help the study. The Aggie researchers are the first U.S. institution in the clinical trial to have federal clearance for testing on humans.
Chancellor Sharp’s $2.5m Makes a Difference
TrialSite News has introduced multiple initiatives worldwide investigating any associations between the BCG vaccine and reductions in COVID-19 related death rates.
Texas A&M recently reported that the university was the lead entity in a world-class group of clinical investigational sites seeking to repurpose the BCG vaccine, which also happens to be used to treat bladder cancer in America.
Chancellor Sharp’s $2.5 million contribution helps to ensure the work of Dr. Jeffrey D. Cirillo can move forward in an expeditious manner. ...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).